The fundamental purpose of Dolofen-F (Ibuprofen) is to provide symptomatic relief across key domains of discomfort, which may assist patients in coping more steadily with acute and chronic manifestations. The therapeutic role of the active ingredient includes its application in managing symptoms that create noticeable physiological strain. It is commonly used in clinical settings marked by heightened patient distress, where short-term symptomatic assistance is needed.

---

Key Therapeutic Applications

Dolofen-F is applied across therapeutic areas that involve acute or disruptive symptom patterns. It is used for managing conditions characterized by episodic manifestations, including pain from headache, toothache, and menstrual cramps (primary dysmenorrhea). Furthermore, it is relevant for easing symptoms related to inflammatory or irritative states, such as the pain and swelling associated with strains, sprains, muscle pain, and chronic conditions like osteoarthritis and rheumatoid arthritis. This medication helps address symptom clusters that may become intense or disruptive, and is commonly used to help with symptoms related to systemic imbalance, such as fever.

“This usage provides supportive therapeutic benefit, and offers symptomatic relief that may assist with easing the overall symptom load during periods where symptoms interfere with daily stability.”

---

Quick Fact

Quick Fact: Relief for Key Symptom Axes	Description
Pain and Discomfort	Supports relief from mild to moderate pain and discomfort associated with acute episodes.
Fever	Contributes to easing symptoms related to systemic imbalance and is relevant for managing elevated body temperature.
Inflammation	Plays a role in managing symptoms related to inflammatory or irritative states, such as localized swelling and stiffness.

---

This medication is generally used when short-term symptomatic assistance is needed, and may contribute to easing the overall symptom load.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Dolofen-F?

Eligibility for Dolofen-F (Ibuprofen) is determined by regulatory authorities based on age, underlying health conditions, and physiological status. Adherence to these official guidelines is essential, as they define absolute prohibitions and conditional use.

---

Contraindicated Populations (Must Not Use)

Dolofen-F is strictly contraindicated for patients with a known history of hypersensitivity reactions to aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Use is also prohibited in those with severe organ failure (heart, kidney, or liver), active or recurrent peptic ulcers/bleeding, and in the last trimester of pregnancy. Furthermore, it must not be used for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

---

Conditional and Restricted Use

Certain groups may use the medicine only with specific limitations, often involving the lowest effective dose for the shortest duration. This includes elderly patients, individuals with mild or moderate renal/hepatic impairment, and patients with a history of inflammatory bowel diseases (like Crohn's disease). High doses are advised against in patients with certain uncontrolled cardiovascular conditions.

---

Age-Specific Eligibility

The medicine is generally established for use in adults and teenagers. For oral liquid formulations, use is typically established in children from 6 months of age, but it is generally not established for infants under 6 months. Use during the first and second trimesters of pregnancy is restricted and generally not recommended unless clearly necessary.

Interactions with other medicines and products

Official regulatory documents describe several categories of medicines and products that may interact with Dolofen-F, requiring specific constraints on use.

---

Documented Interaction Domains

Category	Example Medicine/Substance	Practical Implication
Anticoagulants/Antiplatelets	Warfarin, low-dose Aspirin	Increased risk of bleeding; may reduce Aspirin's cardioprotective effect.
Antihypertensive Agents	ACE Inhibitors, Diuretics	May diminish the blood pressure-lowering and diuretic effects.
Other NSAIDs	Other non-steroidal anti-inflammatory drugs	Combination is generally not recommended due to increased risk of serious side effects.
Specific Narrow-Index Drugs	Lithium, Digoxin	Increased serum concentrations of these drugs, necessitating monitoring of levels.

---

Interaction-Related Constraints

Concomitant use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Cox-2 inhibitors, is advised against due to the heightened potential for adverse effects. When combined with medications that affect blood clotting or those used to treat high blood pressure, close clinical monitoring is required to manage the increased risks. This may include monitoring for signs of bleeding, as well as checking blood pressure and kidney function. Due to the potential for elevated drug levels, serum concentration monitoring is mandatory when co-administering with Lithium or Digoxin. Alcohol consumption should be avoided or limited as it increases the risk of gastrointestinal complications. These constraints define the necessary requirements for safe use as outlined in official labeling.

Dolofen-F (Ibuprofen) operates via a precise enzyme-mediated mechanism that modulates specific enzymatic processes within the eicosanoid system, rather than by affecting neuronal electrical signaling or direct receptor binding. This mechanism relies on altering the production of key biochemical mediators in both the central nervous system ( CNS) and peripheral pathways.

---

Blocking Prostaglandin Synthesis in the Arachidonic Acid Cascade

The drug acts as a reversible, non-selective inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2). These enzymes are essential for the initial step in the Arachidonic Acid Cascade, specifically the conversion of Arachidonic Acid into prostanoids like Prostaglandins ( PGE2) and Thromboxanes. By blocking COX activity, the drug limits the production of these key pro-inflammatory and sensitizing mediators, which results in a measurable reduction of downstream prostanoid-mediated physiological responses.

---

Modulating Peripheral and Central Signaling

The mechanism exerts influence on two distinct physiological sites: peripheral tissue and the hypothalamus in the CNS. Peripherally, the reduced PGE2 concentration reduces the PGE2-mediated sensitization of nociceptors (pain-sensing neurons) at peripheral sites, while centrally, the suppression of PGE2 in the hypothalamus causes the **resetting of the elevated thermal set-point. This dual-action modulation is a core aspect of the drug's mechanism, as it simultaneously affects the chemical drivers of peripheral signaling and central temperature regulation.

Official Administration Guidelines

Dolofen-F, a combination product containing ibuprofen, chlorpheniramine, and phenylephrine, must be used strictly according to instructions found on the approved label or prescribing information.

Dosing and Frequency

Category	Official Guideline
Route of Administration	Oral (Tablet, Capsule, or Suspension).
Standard Adult Dose	One tablet (or dose unit) every 4 hours as necessary (PRN).
Maximum Daily Dose	Do not take more than six tablets (or dose units) in any 24-hour period.
Age Restriction	Do not use in children younger than 12 years of age.

---

Administration Conditions

All users must adhere to specific contextual instructions for proper administration:

• Intake: Take the dose with food or milk if stomach upset occurs. Tablets should be swallowed whole unless otherwise specified on the product label.
• Duration: Use the lowest effective dosage for the shortest duration of time consistent with treatment goals. Do not use for longer than directed.
• Missed Dose: If you miss a scheduled dose, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose. Do not double doses to make up for a missed one.

These official instructions establish the complete procedural framework for product use, defining the exact quantity, timing, and conditions under which the medication must be taken as specified in the product labeling.

Evidence for Use in Acute Pain and Discomfort

The core research on Dolofen-F was conducted through short-term Randomized Controlled Trials (RCTs) involving adults and adolescents experiencing episodic symptoms like headache, toothache, and muscle aches. Researchers examined outcomes related to physical discomfort, monitoring changes in patient-reported outcomes and the duration until change was noticed. Studies suggest there may be a maximum measured outcome (analgesic ceiling) for pain intensity, and data for long-term outcomes regarding recurring acute use are still emerging or remain insufficient.

---

Evidence for Use in Fever (Pyrexia)

Research concerning temperature change has relied primarily on controlled clinical investigations and RCTs in children (pediatric cohorts aged 6 months and older) and adults. Studies explored temporary physiological imbalance by evaluating outcomes such as body temperature measurements. Investigations typically focused on acute, uncomplicated fever, and the evidence is limited regarding complex or recurring fever states.

---

Evidence for Use in Chronic Inflammatory States

For long-term conditions like Osteoarthritis and Rheumatoid Arthritis, research involved medium-to-long term RCTs that enrolled adult patients. Researchers examined outcomes related to inflammatory or irritative states, focusing on changes in joint swelling, morning stiffness, and outcomes reflecting daily functioning. The research design confirms that these studies do not determine whether the agent affects the progression or course of the underlying inflammatory condition, as they concentrate only on symptomatic change.

---

Long-Term Studies and Follow-up

While longer-duration studies exist for chronic conditions, research highlights that follow-up durations were limited in many acute pain trials, and long-term effects are not fully established in that context. The certainty remains low regarding sustained, long-duration symptomatic outcomes in available evidence.

---

Evidence in Special Populations

Specific research was evaluated in children for both temperature change and certain acute pain indications. Studies in this area examined outcomes related to physical discomfort in younger patient groups. However, data for certain groups remain insufficient, and subgroup findings are uncertain regarding the full spectrum of outcomes in those with multiple pre-existing conditions.

---

What is Still Uncertain About Dolofen-F Research

Research highlights that the evidence quality varies across studies, and limitations such as the aforementioned analgesic ceiling apply only to the populations studied. These research gaps mean that existing studies provide limited insight into how outcomes might differ in populations not fully represented in the primary trials.

Key Studies & References

1. WHO Model List of Essential Medicines (23rd List, 2023) - Section 2.1 Non-opioids and NSAIMs (Inclusion/Age Restriction)

Common questions about Dolofen-F (FAQ)

Q: What is the main difference between Dolofen-F and generic pain relievers?

Regulatory documents indicate that Dolofen-F is a combination medicine. It contains the pain reliever Ibuprofen (an NSAID), along with Chlorpheniramine (an antihistamine) and Phenylephrine (a nasal decongestant). This combination differs from generic pain relievers that typically contain only a single active ingredient like Ibuprofen alone.

Q: Are there any common foods or drinks that interact with Dolofen-F?

Official warnings state that consuming alcohol should be avoided or limited while taking this medicine due to an increased risk of serious side effects. Administration guidelines also note that the medicine may be taken with food or milk if stomach discomfort is experienced.

Q: Does Dolofen-F cause drowsiness or affect alertness?

Yes, due to the antihistamine component, this medicine may cause drowsiness. Regulatory warnings advise that patients use caution when driving, operating machinery, or engaging in activities that require full mental alertness until they observe how the medicine affects them.

Q: Do studies show that Dolofen-F can be taken by older adults?

Regulatory documents include elderly patients under conditional and restricted use. Regulatory documents describe use in this population as generally limited to the lowest effective dose for the shortest duration. Specific constraints described in official labeling may include the need for close clinical monitoring.

Q: Are there documented cases of Dolofen-F affecting sleep patterns?

Yes. Official labels indicate that the product contains ingredients that can cause both drowsiness and excitability or nervousness. These documented effects may potentially interfere with normal sleep patterns for some individuals.

Q: Does Dolofen-F have a generic version available?

The active ingredient Ibuprofen is widely available as a generic medicine. The specific combination product (Ibuprofen with Chlorpheniramine and Phenylephrine) is registered under its specific name, and the availability of its generic equivalent depends on separate market approvals by health authorities.

Q: How does Dolofen-F differ from ibuprofen or acetaminophen?

Dolofen-F differs from single-ingredient Ibuprofen by including an antihistamine and a decongestant. It differs from Acetaminophen because it belongs to the NSAID class, meaning it provides anti-inflammatory action as well as pain relief, which Acetaminophen does not.

Q: Do regulatory bodies list any specific dietary requirements with Dolofen-F?

Official guidelines describe taking the dose with food or milk if stomach upset is experienced. Outside of the general constraint against alcohol consumption, there are no other specific, mandatory dietary restrictions listed in the official documents.

Q: How quickly does Dolofen-F usually start working?

According to the official clinical information, the onset of relief from Dolofen-F is typically observed within 30 to 60 minutes after administration.

Q: What is the expected length of time for the effects of Dolofen-F to last?

Regulatory documents indicate the duration of action. The effects of the medicine typically last for the period specified in the official dosage instructions, which is commonly 4 to 6 hours.

Q: Can Dolofen-F be taken while I am taking supplements?

Regulatory documents describe the need for caution when combining this medicine with other products, including supplements. This is especially true for supplements that affect blood clotting or cause central nervous system effects like drowsiness or stimulation.

Q: Is Dolofen-F considered a controlled substance in the US?

No. Official classification by regulatory agencies states that none of the active ingredients in this combination product (Ibuprofen, Chlorpheniramine, or Phenylephrine) are classified as controlled substances.

Q: How long after taking Dolofen-F does it reach its highest concentration?

Regulatory documents provide pharmacokinetic information indicating that the peak plasma concentration (T max) for the active ingredients is typically reached within one to two hours after administration.

Q: Can Dolofen-F affect the results of lab tests?

Official labels may list specific tests that can be affected by the medicine. Regulatory information suggests that patients inform the laboratory and their healthcare provider that they are taking this product before testing.

Q: Is a prescription always required for Dolofen-F?

At the dosages commonly available for this combination, Dolofen-F is typically regulated as an Over-the-Counter (OTC) product by health authorities, meaning a prescription is not required for purchase.

Q: What information is provided about potential interactions with herbal remedies?

Official information generally emphasizes the need for caution regarding herbal remedies, particularly those that may affect blood clotting or cause central nervous system effects, which could increase the risk of side effects from Dolofen-F.

Q: What is the current safety classification status of Dolofen-F?

Dolofen-F is classified by regulatory agencies as an analgesic (pain reliever), antipyretic (fever reducer), anti-inflammatory, antihistamine, and nasal decongestant combination medicine.

Q: Is it possible to become dependent on Dolofen-F?

No. Official labeling includes a section on abuse and dependence. The active ingredients in Dolofen-F are not classified as having a risk of abuse or dependence.

Q: How long has Dolofen-F been approved for use?

The foundational ingredient, Ibuprofen, has been approved for use for several decades. The specific combination product has a regulatory approval date filed with the respective health authority, confirming its official status for marketing.

Q: Is the active ingredient in Dolofen-F related to opioids?

No. Official product descriptions classify the main active ingredient, Ibuprofen, as an NSAID (Non-Steroidal Anti-Inflammatory Drug). This pharmacological class is entirely distinct and not chemically related to the opioid class of pain relievers.

How to Store and Dispose of Dolofen-F

The storage and disposal of Dolofen-F (Ibuprofen) are governed by official regulatory requirements to ensure product stability and safety.

Storage Conditions

Requirement	Specification
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Heat Restriction	Avoid excessive heat above 40 C (104 F).
Protection	Keep the product protected from light and moisture and store in a tight container.

Disposal and Safety

The medicine must be kept out of the sight and reach of children.

Disposal of any unused or expired Dolofen-F must be carried out in accordance with local regulatory requirements. Official guidance advises against flushing the product into surface water due to environmental risk, recommending the use of authorized drug take-back programs.